Skip to content
Clinical Trials – home
Therapeutic area

Nervous system disorders – page 34

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Hereditary ataxia+1

Recruiting

Study on the Safety of VO659 for Patients with Spinocerebellar Ataxia Types 1, 3, and Huntington's Disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Vo659
  • Sponsor:Vico Therapeutics B.V.

Evaluating the effects of intravenous melatonin for preventing agitation and emergence delirium in children undergoing elective surgery

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Melatonin
  • Sponsor:Region Hovedstaden

Study of Eculizumab in Adults with Hypertensive Emergency-Related Hemolytic Uremic Syndrome Requiring Dialysis or with Severe Kidney Problems

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Eculizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Human Plasma Protein vs. Crystalloid for Fluid Management in Children with Scoliosis Undergoing Spinal Fusion Surgery

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:Human Plasma Protein
  • Sponsor:HUS-Yhtymae

Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Medica Scientia Innovation Research S.L.

Neuroblastoma+1

Recruiting

Study of ABTL0812, Irinotecan, and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Irinotecan
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Study on Apathy in Stroke Patients Using Fluoroethoxybenzovesamicol F-18 and Fluorodopa (18F)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorodopa (18F)
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Study on Istradefylline for Reducing Brain Inflammation in Patients with Progressive Multiple Sclerosis

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Istradefylline
  • Sponsor:University Of Turku

Study on Neural Stem Cell and Sodium Chloride Treatment for Patients with Amyotrophic Lateral Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Sodium Chloride Ph. Eur.
  • Sponsor:Casa Sollievo Della Sofferenza

Study of [18F]AlF-NOTA-Octreotide for Carotid Artery Disease in Patients with Recent Stroke or TIA

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[18F]Alf-Nota-Octreotide
  • Sponsor:UZ Leuven

Study on Tenecteplase and Alteplase for Patients with Acute Ischemic Stroke Due to Basilar Artery Blockage

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.